The purpose of this study is to learn about: - effects of living with COVID-19 and - how effective is nirmatrelvir-ritonavir in treating COVID-19.This is a study of two groups of COVID-19 patients in Taiwan.In Group 1 the below participants were included in the study: - Patients of all ages. - Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021. - Cases of patients registered in the databases.In Group 2 the below participants were included in the study: - Participants who are 12 years or older. - Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022.Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19.The study will look at: - the nature of Covid-19 disease. - as well as the experiences of people receiving the nirmatrelvir-ritonavir.This study will help to: - understand what type of patients will need to be admitted to hospitals. - see severe results due to COVID 19 infection. - have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.
Not Provided
Drug: SoC
COVID-19 treatment as per government guidance
Other: Disease description
No intervention
Cohort 1:
Inclusion Criteria:
- Patients of all ages
- Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31
December 2021
- Cases of patients registered in the databases
Exclusion Criteria:
- Patients without COVID-19 diagnosis
Cohort 2:
Inclusion Criteria:
- ≥12 years of age
- Have COVID-19 diagnosis with international classification of diseases (ICD) code
between 01 January 2022 and 31 December 2022
Exclusion Criteria:
- Patients without COVID-19 diagnosis
Pfizer Limited
Taipei, Taiwan
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Pfizer CT.gov Call Center, Study Director
Pfizer